MarketCap
Facebook
X
TelegramQuartalsbericht 2023-Q3
hinzugefügt 06.11.2023
NanoString Technologies Zahlungsmittel 2011-2026 | NSTG
Zahlungsmittel Jährlich NanoString Technologies
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 112 M | 107 M | 412 M | 29 M | 24.4 M | 26.1 M | 20.6 M | 21.9 M | 17.2 M | 9.94 M | 21.7 M | 10.9 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 412 M | 9.94 M | 67.7 M |
Zahlungsmittel Vierteljährlich NanoString Technologies
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 93.8 M | 114 M | 121 M | 112 M | 117 M | 126 M | 98.5 M | 107 M | 107 M | 160 M | 397 M | 412 M | 412 M | 412 M | 412 M | 29 M | 29 M | 29 M | 29 M | 24.4 M | 24.4 M | 24.4 M | 24.4 M | 26.1 M | 26.1 M | 26.1 M | 26.1 M | 20.6 M | 20.6 M | 20.6 M | 20.6 M | 21.9 M | 21.9 M | 21.9 M | 21.9 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 9.94 M | 9.94 M | 9.94 M | 9.94 M | 21.7 M | 21.7 M | 21.7 M | - | 10.9 M | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 412 M | 9.94 M | 82.4 M |
Zahlungsmittel anderer Aktien in der Pharmaeinzelhändler
| Name | Zahlungsmittel | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aligos Therapeutics
ALGS
|
18.3 M | $ 6.4 | - | $ 63.3 M |  USA |
 |
Amphastar Pharmaceuticals
AMPH
|
170 M | $ 21.41 | - | $ 1 B | USA |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
8.53 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aptorum Group Limited
APM
|
3.5 M | $ 0.9 | -2.33 % | $ 6.62 M | China |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
320 M | $ 21.96 | - | $ 3.64 B | USA |
 |
Cardiff Oncology
CRDF
|
17.5 M | $ 1.72 | - | $ 115 M | USA |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
AIkido Pharma
AIKI
|
34 M | - | 1.93 % | $ 17.4 M | USA |
 |
Esperion Therapeutics
ESPR
|
168 M | $ 1.91 | - | $ 397 M | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Galectin Therapeutics
GALT
|
17.7 M | $ 2.33 | - | $ 149 M | USA |
 |
Allakos
ALLK
|
66.4 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
98.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
7.31 M | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
29 K | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
49.9 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | USA |
 |
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
53.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
4.88 M | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
7.68 B | $ 105.46 | - | $ 27.2 B | Germany |
 |
Heron Therapeutics
HRTX
|
28.6 M | $ 1.19 | - | $ 198 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.86 M | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
ImmuCell Corporation
ICCC
|
3.81 M | $ 8.36 | - | $ 75.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
121 M | $ 4.08 | - | $ 436 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
42.9 M | $ 23.26 | - | $ 2.96 B | USA |
 |
InflaRx N.V.
IFRX
|
16 M | $ 1.48 | - | $ 152 M | Germany |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
104 M | $ 1.44 | - | $ 383 M | Britain |
 |
Aptose Biosciences
APTO
|
935 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Innate Pharma S.A.
IPHA
|
28.1 M | $ 1.41 | - | $ 235 M | France |
 |
AstraZeneca PLC
AZN
|
5.71 B | - | - | $ 96.9 B | Britain |
 |
Jaguar Health
JAGX
|
968 K | $ 0.39 | -0.18 % | $ 910 K | USA |
 |
AVROBIO
AVRO
|
98 M | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
8.27 M | $ 2.91 | - | $ 4.79 M | Israel |
 |
KalVista Pharmaceuticals
KALV
|
229 M | $ 19.63 | - | $ 1.06 B | Britain |
 |
BioDelivery Sciences International
BDSI
|
112 M | - | -4.8 % | $ 255 M | USA |
 |
Kamada Ltd.
KMDA
|
75.5 M | $ 8.28 | - | $ 260 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
4.55 B | - | 0.49 % | $ 251 B |  Cayman-islands |